The American Association for Thoracic Surgery (AATS) 2023 Expert Consensus Document: Staging and multidisciplinary management of patients with early-stage non-small cell lung cancer.

[1]  M. Tsuboi,et al.  Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. , 2022, The Lancet. Oncology.

[2]  Javier M. Martín-López,et al.  Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial) , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Joe Y. Chang,et al.  Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[5]  Kenji Suzuki,et al.  Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial , 2022, The Lancet.

[6]  R. Stupp,et al.  Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials , 2022, ESMO open.

[7]  V. Calvo,et al.  Treatment Sequencing in Resectable Lung Cancer: The Good and the Bad of Adjuvant Versus Neoadjuvant Therapy. , 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[8]  R. Govindan,et al.  Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). , 2022, JAMA oncology.

[9]  Jingyuan Xie,et al.  Effect of Adjuvant Chemotherapy on Survival of Patients With 8th Edition Stage IB Non-Small Cell Lung Cancer , 2022, Frontiers in Oncology.

[10]  J. Dunning,et al.  Video-Assisted Thoracoscopic or Open Lobectomy in Early-Stage Lung Cancer. , 2022, NEJM evidence.

[11]  Y. Shyr,et al.  Preoperative and Postoperative Systemic Therapy for Operable Non-Small-Cell Lung Cancer. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Zalcberg,et al.  Impacts of lung cancer multidisciplinary meeting presentation: Drivers and outcomes from a population registry retrospective cohort study. , 2021, Lung Cancer.

[13]  O. Riesterer,et al.  Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. , 2021, The Lancet. Oncology.

[14]  M. Tsuboi,et al.  Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT) , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Takano,et al.  Revisiting neoadjuvant therapy in non-small-cell lung cancer. , 2021, The Lancet. Oncology.

[16]  A. Chella,et al.  Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial , 2021, The Lancet.

[17]  Baofu Chen,et al.  Pulmonary function after segmentectomy versus lobectomy in patients with early-stage non-small-cell lung cancer: a meta-analysis , 2021, The Journal of international medical research.

[18]  N. Altorki,et al.  Outcomes Following Surgical Resection of Early-Stage Lung Adenocarcinomas with EGFR mutations. , 2021, The Annals of thoracic surgery.

[19]  David R. Jones,et al.  Shape-Sensing Robotic-Assisted Bronchoscopy in the Diagnosis of Pulmonary Parenchymal Lesions. , 2021, Chest.

[20]  Jiang Liu,et al.  FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review , 2021, Clinical Cancer Research.

[21]  M. Okada,et al.  Adjuvant chemotherapy for high-risk pathological stage I non-small cell lung cancer. , 2021, The Annals of thoracic surgery.

[22]  Jie He,et al.  Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non–Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy , 2021, JAMA oncology.

[23]  K. Hunt,et al.  American College of Surgeons Commission on Cancer Standard for Curative Intent Pulmonary Resection. , 2021, The Annals of thoracic surgery.

[24]  Carmelo Gaudioso,et al.  Impact of a Thoracic Multidisciplinary Conference on Lung Cancer Outcomes. , 2021, The Annals of thoracic surgery.

[25]  Yong-Hee Kim,et al.  A Validation Study on the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients with pN2 Non-small Cell Lung Cancer. , 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Ying Cheng,et al.  Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Spaggiari,et al.  Anatomical segmentectomy versus pulmonary lobectomy for stage I non-small-cell lung cancer: patients selection and outcomes from the European Society of Thoracic Surgeons database analysis. , 2020, Interactive cardiovascular and thoracic surgery.

[28]  M. Aznar,et al.  Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[29]  Y. Takeshima,et al.  Segmentectomy vs. lobectomy for clinical stage IA lung adenocarcinoma with spread through air spaces. , 2020, The Annals of thoracic surgery.

[30]  F. Tan,et al.  Influence of adjuvant chemotherapy on survival for patients with stage IB and IIA non‐small cell lung cancer , 2020, Thoracic cancer.

[31]  M. Tsuboi,et al.  Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. , 2020, The New England journal of medicine.

[32]  D. Boffa,et al.  Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. , 2020, JAMA oncology.

[33]  Raymond Y Huang,et al.  Diagnostic Yield of Staging Brain MRI in Patients with Newly Diagnosed Non-Small Cell Lung Cancer. , 2020, Radiology.

[34]  T. Gildea,et al.  Robotic Bronchoscopy for Peripheral Pulmonary Lesions , 2020, Chest.

[35]  Sukki Cho,et al.  Predictive Factors for Lymph Node Metastasis in Clinical Stage I Part-Solid Lung Adenocarcinoma. , 2020, The Annals of thoracic surgery.

[36]  R. Osarogiagbon,et al.  Survival after mediastinal node dissection, systematic sampling or neither for early-stage non-small-cell lung cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[37]  Y. Tsutani,et al.  Oncologic outcomes of lobectomy vs. segmentectomy in non-small cell lung cancer with clinical T1N0M0 stage: a literature review and meta-analysis , 2020, Journal of thoracic disease.

[38]  Yong-Hee Kim,et al.  Comparison of prognostic impact of lymphovascular invasion in stage IA non-small cell lung cancer after lobectomy versus sublobar resection: A propensity score-matched analysis. , 2020, Lung cancer.

[39]  D. Boffa,et al.  Equivalent survival between lobectomy and segmentectomy for clinical stage IA lung cancer. , 2020, The Annals of thoracic surgery.

[40]  Y. Mao,et al.  Oncologic outcomes of segmentectomy vs lobectomy in pathologic stage IA (≤2 cm) invasive lung adenocarcinoma: A population‐based study , 2020, Journal of surgical oncology.

[41]  J. Taube,et al.  Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.

[42]  P. D. De Leyn,et al.  Segmentectomy or lobectomy for early-stage non-small-cell lung cancer: a systematic review and meta-analysis. , 2020, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[43]  R. Osarogiagbon,et al.  Beyond Margin Status: Population-Based Validation of the Proposed IASLC Residual Tumor Classification Re-categorization. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[44]  Ying Cheng,et al.  Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. , 2019, The New England journal of medicine.

[45]  Guang-qiang Zhao,et al.  Meta-analysis of segmentectomy versus lobectomy for radiologically pure solid or solid-dominant stage IA non-small cell lung cancer , 2019, Journal of Cardiothoracic Surgery.

[46]  A. Nicholson,et al.  The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[47]  H. Dienemann,et al.  Perioperative course and quality of life in a prospective randomized multicenter phase III trial, comparing standard lobectomy versus anatomical segmentectomy in patients with non-small cell lung cancer up to 2 cm, stage IA (7th edition of TNM staging system). , 2019, Lung cancer.

[48]  W. Liang,et al.  The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis. , 2019, The Annals of thoracic surgery.

[49]  N. Altorki,et al.  Extent of lymphadenectomy is associated with oncological efficacy of sublobar resection for lung cancer ≤2 cm. , 2019, The Journal of thoracic and cardiovascular surgery.

[50]  M. Kris,et al.  Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  M. Kris,et al.  SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  David R. Jones,et al.  Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). , 2018, The Lancet. Respiratory medicine.

[53]  B. Han,et al.  Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion , 2018, The Journal of thoracic and cardiovascular surgery.

[54]  W. Mao,et al.  Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. , 2018, The Lancet. Respiratory medicine.

[55]  D. Planchard,et al.  Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC , 2018, The New England journal of medicine.

[56]  T. Demmy,et al.  Effect of the number of lymph nodes examined on the survival of patients with stage I non–small cell lung cancer who undergo sublobar resection , 2018, The Journal of thoracic and cardiovascular surgery.

[57]  David R. Jones,et al.  Feasibility of endobronchial ultrasound transbronchial needle aspiration for massively parallel next-generation sequencing in thoracic cancer patients. , 2018, Lung cancer.

[58]  Stephen Broderick,et al.  Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.

[59]  M. Berry,et al.  Survival after radiation for stage I and II non-small cell lung cancer with positive margins. , 2018, The Journal of surgical research.

[60]  J. Howington,et al.  Improved Lymph Node Staging in Early-Stage Lung Cancer in the National Cancer Database. , 2017, The Annals of thoracic surgery.

[61]  Shun‐ichi Watanabe,et al.  Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[62]  Sin-Ho Jung,et al.  Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2‐Positive Non‐Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  J. Horton,et al.  A Phase II Study of Pembrolizumab in EGFR‐Mutant, PD‐L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[64]  Hui Zhang,et al.  Lymph node dissection and survival in patients with early stage nonsmall cell lung cancer , 2017, Medicine.

[65]  G. Migliaretti,et al.  Assessing the prognostic impact of the International Association for the Study of Lung Cancer proposed definitions of complete, uncertain, and incomplete resection in non-small cell lung cancer surgery. , 2017, Lung cancer.

[66]  A. Jemal,et al.  Survival impact of postoperative therapy modalities according to margin status in non–small cell lung cancer patients in the United States , 2017, The Journal of thoracic and cardiovascular surgery.

[67]  T. Treasure,et al.  Systematic lymphadenectomy versus sampling of ipsilateral mediastinal lymph-nodes during lobectomy for non-small-cell lung cancer: a systematic review of randomized trials and a meta-analysis , 2017, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[68]  M. Underwood,et al.  Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[69]  T. Go,et al.  Customized Adjuvant Chemotherapy Based on Biomarker Examination May Improve Survival of Patients Completely Resected for Non-small-cell Lung Cancer. , 2017, Anticancer research.

[70]  M. Kris,et al.  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  L. Svensson,et al.  The American Association for Thoracic Surgery/Society of Thoracic Surgeons position statement on developing clinical practice documents. , 2017, The Journal of thoracic and cardiovascular surgery.

[72]  Carlos Barrios,et al.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.

[73]  E. Miyaoka,et al.  Lobe‐Specific Nodal Dissection for Clinical Stage I and II NSCLC: Japanese Multi‐Institutional Retrospective Study Using a Propensity Score Analysis , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[74]  J. Putnam,et al.  Rationale for a Minimum Number of Lymph Nodes Removed with Non-Small Cell Lung Cancer Resection: Correlating the Number of Nodes Removed with Survival in 98,970 Patients , 2016, Annals of Surgical Oncology.

[75]  A. Toker,et al.  Lymph Node Dissection in Surgery for Lung Cancer: Comparison of Open vs. Video-Assisted vs. Robotic-Assisted Approaches. , 2016, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[76]  Yiping Wei,et al.  Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Lymph Node Dissection in Clinical Stage I Lung Cancer: A Meta-Analysis and System Review. , 2016, The Annals of thoracic surgery.

[77]  Y. Shentu,et al.  Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.

[78]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[79]  G. Colditz,et al.  Pathologic Upstaging in Patients Undergoing Resection for Stage I Non-Small Cell Lung Cancer: Are There Modifiable Predictors? , 2015, The Annals of thoracic surgery.

[80]  S. Ramalingam,et al.  Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[81]  C. Rudin,et al.  Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[82]  R. Mirimanoff,et al.  Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial , 2015, The Lancet.

[83]  Chun-Ming Tsai,et al.  Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  Yang Zhang,et al.  Meta‐analysis of lobectomy, segmentectomy, and wedge resection for stage I non‐small cell lung cancer , 2015, Journal of surgical oncology.

[85]  J. Choi,et al.  Endobronchial Ultrasound versus Mediastinoscopy for Mediastinal Nodal Staging of Non–Small-Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[86]  Jiang Du,et al.  Systematic Mediastinal Lymphadenectomy or Mediastinal Lymph Node Sampling in Patients With Pathological Stage I NSCLC: A Meta-Analysis , 2015, World Journal of Surgery.

[87]  David R. Jones,et al.  Differences in patterns of recurrence in early-stage versus locally advanced non-small cell lung cancer. , 2014, The Annals of thoracic surgery.

[88]  Qiao Chen,et al.  Mediastinal Lymph Node Dissection versus Mediastinal Lymph Node Sampling for Early Stage Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis , 2014, PloS one.

[89]  J. Luketich,et al.  Recurrence and survival outcomes after anatomic segmentectomy versus lobectomy for clinical stage I non-small-cell lung cancer: a propensity-matched analysis. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[90]  D. Sher,et al.  Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non‐small cell lung cancer in the National Cancer Data Base , 2014, Cancer.

[91]  R. Cerfolio,et al.  The prevalence of nodal upstaging during robotic lung resection in early stage non-small cell lung cancer. , 2014, The Annals of thoracic surgery.

[92]  Sarah Burdett,et al.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data , 2014, The Lancet.

[93]  S. Broderick,et al.  Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy. , 2014, The Journal of thoracic and cardiovascular surgery.

[94]  H. Saito,et al.  Pulmonary Function After Lobectomy Versus Segmentectomy in Patients with Stage I Non-Small Cell Lung Cancer , 2014, World Journal of Surgery.

[95]  C. Henschke,et al.  Sublobar resection is equivalent to lobectomy for clinical stage 1A lung cancer in solid nodules. , 2014, The Journal of thoracic and cardiovascular surgery.

[96]  Andrew M Breglio,et al.  Lobe-specific mediastinal nodal dissection is sufficient during lobectomy by video-assisted thoracic surgery or thoracotomy for early-stage lung cancer. , 2013, Chest.

[97]  P. Licht,et al.  A national study of nodal upstaging after thoracoscopic versus open lobectomy for clinical stage I lung cancer. , 2013, The Annals of thoracic surgery.

[98]  Masahiko Kusumoto,et al.  Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan Clinical Oncology Group 0201. , 2013, The Journal of thoracic and cardiovascular surgery.

[99]  H. Kondo,et al.  Recurrence of mediastinal node cancer after lobe-specific systematic nodal dissection for non-small-cell lung cancer. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[100]  F. Shepherd,et al.  Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based study. , 2013, Current oncology.

[101]  Y. Nishimura,et al.  A phase 3 study of induction treatment with concurrent chemoradiotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) , 2012, Cancer.

[102]  R. Osarogiagbon,et al.  Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non–Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results Database , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[103]  P. Ellis,et al.  Improving referral of patients for consideration of adjuvant chemotherapy after surgical resection of lung cancer. , 2012, Current oncology.

[104]  Wenhu Chen,et al.  Comparison of thoracoscopic segmentectomy and thoracoscopic lobectomy for small-sized stage IA lung cancer. , 2012, The Annals of thoracic surgery.

[105]  D. Boffa,et al.  Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. , 2012, The Annals of thoracic surgery.

[106]  M. Berry,et al.  Lymphovascular Invasion in Non–Small-Cell Lung Cancer: Implications for Staging and Adjuvant Therapy , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[107]  R. Pietrobon,et al.  Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. , 2012, The Annals of thoracic surgery.

[108]  D. Gossot,et al.  Mediastinal lymph node dissection in early-stage non-small cell lung cancer: totally thoracoscopic vs thoracotomy. , 2012, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[109]  G. da Cunha Santos,et al.  A prospective controlled trial of endobronchial ultrasound-guided transbronchial needle aspiration compared with mediastinoscopy for mediastinal lymph node staging of lung cancer. , 2011, The Journal of thoracic and cardiovascular surgery.

[110]  Y. Ung,et al.  Positron Emission Tomography-Computed Tomography Compared with Invasive Mediastinal Staging in Non-small Cell Lung Cancer: Results of Mediastinal Staging in the Early Lung Positron Emission Tomography Trial , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[111]  J. Niland,et al.  Efficacy of mediastinal lymph node dissection during lobectomy for lung cancer by thoracoscopy and thoracotomy. , 2011, The Annals of thoracic surgery.

[112]  V. Rusch,et al.  Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. , 2011, The Journal of thoracic and cardiovascular surgery.

[113]  M. Ladanyi,et al.  Reflex testing of resected stage I through III lung adenocarcinomas for EGFR and KRAS mutation: report on initial experience and clinical utility at a single center. , 2011, The Journal of thoracic and cardiovascular surgery.

[114]  J. Padilla,et al.  Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  J. Gimferrer,et al.  Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. , 2010, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[116]  K. Matsuo,et al.  Effect of selective lymph node dissection based on patterns of lobe-specific lymph node metastases on patient outcome in patients with resectable non-small cell lung cancer: a large-scale retrospective cohort study applying a propensity score. , 2010, The Journal of thoracic and cardiovascular surgery.

[117]  L. Marks,et al.  Timing of Local and Distant Failure in Resected Lung Cancer: Implications for Reported Rates of Local Failure , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[118]  J. Pignon,et al.  Adjuvant Cisplatin and Vinorelbine for Completely Resected Non-small Cell Lung Cancer: Subgroup Analysis of the Lung Adjuvant Cisplatin Evaluation , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[119]  Y. Ung,et al.  Positron Emission Tomography in Staging Early Lung Cancer , 2009, Annals of Internal Medicine.

[120]  V. Rusch,et al.  Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.

[121]  Richard J Stephens,et al.  Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  F. Herth,et al.  Diagnosis of Mediastinal Adenopathy—Real-Time Endobronchial Ultrasound Guided Needle Aspiration versus Mediastinoscopy , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[123]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[124]  M. Coory,et al.  Systematic review of multidisciplinary teams in the management of lung cancer. , 2008, Lung cancer.

[125]  Michael Wallace,et al.  Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.

[126]  Atul C Mehta,et al.  Evidence-Based Clinical Practice Guidelines Initial Diagnosis of Lung Cancer : ACCP , 2007 .

[127]  F. Shepherd,et al.  Referral Patterns for Adjuvant Chemotherapy in Patients with Completely Resected Non-small Cell Lung Cancer , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[128]  V. Rousson,et al.  Morbidity, survival, and site of recurrence after mediastinal lymph-node dissection versus systematic sampling after complete resection for non-small cell lung cancer. , 2005, The Annals of thoracic surgery.

[129]  M. Conron,et al.  The accuracy of EUS-FNA in assessing mediastinal lymphadenopathy and staging patients with NSCLC , 2005, European Respiratory Journal.

[130]  M. Ando,et al.  Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer. , 2004, Lung cancer.

[131]  V. Rusch,et al.  Induction chemoradiation and surgical resection for non-small cell lung carcinomas of the superior sulcus: Initial results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). , 2001, The Journal of thoracic and cardiovascular surgery.

[132]  K. Mori,et al.  Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. , 1999, Chest.

[133]  U. Pastorino,et al.  Systematic nodal dissection in the intrathoracic staging of patients with non-small cell lung cancer. , 1999, The Journal of thoracic and cardiovascular surgery.

[134]  M. Mack,et al.  Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer. , 1997, The Journal of thoracic and cardiovascular surgery.

[135]  L V Rubinstein,et al.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. , 1995, The Annals of thoracic surgery.

[136]  D. Hunter,et al.  Qualitative Research: Consensus methods for medical and health services research , 1995 .

[137]  J. Roth,et al.  A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. , 1994, Journal of the National Cancer Institute.

[138]  J. Mate,et al.  A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. , 1994, The New England journal of medicine.

[139]  N. Ak,et al.  The role of adjuvant chemotherapy in resected stage I non - small cell lung cancer: A Turkish Oncology Group Study. , 2021, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[140]  N. Altorki,et al.  Segmentectomy Is Equivalent to Lobectomy in Hypermetabolic Clinical Stage IA Lung Adenocarcinomas. , 2019, The Annals of thoracic surgery.

[141]  R. Osarogiagbon,et al.  Association of Pathologic Nodal Staging Quality With Survival Among Patients With Non–Small Cell Lung Cancer After Resection With Curative Intent , 2018, JAMA oncology.

[142]  M. Tsuboi,et al.  Lobe‐Specific Lymph Node Dissection as a Standard Procedure in Surgery for Non–Small Cell Lung Cancer: A Propensity Score Matching Study , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[143]  David R Jones,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. , 2016, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[144]  R. Rintoul,et al.  Stage migration: results of lymph node dissection in the era of modern imaging and invasive staging for lung cancer. , 2013, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

[145]  Armin Thron,et al.  Diagnostic Accuracy of MRI Compared to CCT in Patients with Brain Metastases , 2004, Journal of Neuro-Oncology.